Abstract 3D rendering of cells and molecules representing cell and gene therapy research

Engineering Clinical Development for Novel Therapeutics: CGT and Beyond

Webinar

Want to invite a colleague to this FREE webinar?

Fill out the form below and we'll send your colleague an invitation to the "Engineering Clinical Development for Novel Therapeutics: CGT and Beyond" event.

As the cell and gene therapy (CGT) field continues to mature, many companies face a growing tension between scientific innovation and the realities of clinical development. Unsustainable costs, limited access to specialized expertise and outdated operational models contribute to high failure rates and stalled progress.

In this webinar, Vishal Mehta and Jeffrey Yablon from Ubuntu Research will explore a knowledge-driven approach to clinical development, drawing on strategies from industries built around shared expertise and agile, on-demand support. They will also discuss a real-world case study with a mid-stage oncology cell therapy company, highlighting how rethinking planning, governance and team structure helped navigate key clinical hurdles.

By attending this webinar, you will learn:

How CGT companies can adopt more adaptive, scalable clinical development models
Strategies to overcome common operational and compliance challenges
Lessons from an oncology case study on navigating early-phase clinical transition

Engineering Clinical Development for Novel Therapeutics: CGT and Beyond As the cell and gene therapy (CGT) field continues to mature, many companies face a growing tension between scientific innovation and the realities of clinical development. Unsustainable costs, limited access to specialized expertise and outdated operational models contribute to high failure rates and stalled progress. In this webinar, Vishal Patel and Jeffrey Yablon from Ubuntu Research will explore a knowledge-driven approach to clinical development, drawing on strategies from industries built around shared expertise and agile, on-demand support. They will also discuss a real-world case study with a mid-stage oncology cell therapy company, highlighting how rethinking planning, governance and team structure helped navigate key clinical hurdles. By attending this webinar, you will learn: • How CGT companies can adopt more adaptive, scalable clinical development models • Strategies to overcome common operational and compliance challenges • Lessons from an oncology case study on navigating early-phase clinical transition Vishal Mehta and Jeffrey Yablon Vishal – CEO/ Jeffrey – Head BD and Strategic Operations Ubuntu Research Vishal Mehta founded Ubuntu Research Inc. to accelerate the delivery of innovative therapies in a sustainable and modern way. With over 20 years of experience spanning pharma, biotech, and CRO sectors, he brings deep expertise in drug development strategy, clinical execution, and agile operations. Vishal has contributed to numerous impactful therapies, including CAR T treatments BREYANZI® and ABECMA®, targeted therapies KISQALI® and AFINITOR®, the immunotherapy YERVOY®, biosimilars, and various life cycle management programs in oncology and beyond. He holds a B.S. in Pharmaceutical Sciences from the University of Mumbai and an M.S. in Clinical Research & Administration from George Washington University. Jeffrey Scott Yablon serves as Executive Consultant for Business Development at Ubuntu Research Inc., focusing on strategic partnerships and market adoption of the DIMENSION-T™ platform. A U.S. Army veteran and life sciences leader, Jeff holds a BA from Stockton University and an EMBA from Fairleigh Dickinson University. With 30 years of experience in pharma, med-tech, and clinical development, his leadership spans clinical ops, investor relations, and enterprise strategy. He has held senior roles at Frontage Laboratories, InClinica Inc., and Jigsaw Clinical, and began his career with Abbott, Parexel, and ICON. Jeff is currently an advisor at Cogmotos Inc., supporting investor engagement and operations, and has contributed to academia through teaching and board roles. He is recognized for advancing clinical research across Asia-Pacific.

Speakers